{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:02:48Z","timestamp":1792803768413,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Med Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antimicrobial resistance is a hidden threat lurking behind the COVID-19 pandemic which has claimed thousands of lives prior to the emergence of the global outbreak. With a pandemic on the scale of COVID-19, antimicrobial resistance has the potential to become a double-edged sword with the overuse of antibiotics having the potential of taking us back to the pre-antibiotic era. Antimicrobial resistance is majorly attributed to widespread and unnecessary use of antibiotics, among other causes, which has facilitated the emergence and spread of resistant pathogens. Our study aimed to conduct a rapid review of national treatment guidelines for COVID-19 in 10 African countries (Ghana, Kenya, Uganda, Nigeria, South Africa, Zimbabwe, Botswana, Liberia, Ethiopia, and Rwanda) and examined its implication for antimicrobial resistance response on the continent. Our findings revealed that various antibiotics, such as azithromycin, doxycycline, clarithromycin, ceftriaxone, erythromycin, amoxicillin, amoxicillin-clavulanic acid, ampicillin, gentamicin, benzylpenicillin, piperacillin\/tazobactam, ciprofloxacin, ceftazidime, cefepime, vancomycin, meropenem, and cefuroxime among others, were recommended for use in the management of COVID-19. This is worrisome in that COVID-19 is a viral disease and only a few COVID-19 patients would have bacterial co-infection. Our study highlighted the need to emphasize prudent and judicious use of antibiotics in the management of COVID-19 in Africa.<\/jats:p>","DOI":"10.1186\/s41182-021-00344-w","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:04:21Z","timestamp":1624435461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["The use of antibiotics in COVID-19 management: a rapid review of national treatment guidelines in 10 African countries"],"prefix":"10.1186","volume":"49","author":[{"given":"Yusuff Adebayo","family":"Adebisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafisat Dasola","family":"Jimoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Olushola","family":"Ogunkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-0211","authenticated-orcid":false,"given":"Theogene","family":"Uwizeyimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaka Hassan","family":"Olayemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson Ashinedu","family":"Ukor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Don Eliseo","family":"Lucero-Prisno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"344_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s41256-020-00148-1","volume":"5","author":"DE Lucero-Prisno 3rd","year":"2020","unstructured":"Lucero-Prisno DE 3rd, Adebisi YA, Lin X. Current efforts and challenges facing responses to 2019-nCoV in Africa. Glob Health Res Policy. 2020;5:21. Published 2020 May 6. https:\/\/doi.org\/10.1186\/s41256-020-00148-1.","journal-title":"Glob Health Res Policy"},{"issue":"Suppl 2","key":"344_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.11604\/pamj.supp.2020.35.2.23671","volume":"35","author":"W Akande-Sholabi","year":"2020","unstructured":"Akande-Sholabi W, Adebisi YA. The impact of COVID-19 pandemic on medicine security in Africa: Nigeria as a case study. Pan Afr Med J. 2020;35(Suppl 2):73. Published 2020 Jun 10. https:\/\/doi.org\/10.11604\/pamj.supp.2020.35.2.23671.","journal-title":"Pan Afr Med J"},{"key":"344_CR3","doi-asserted-by":"publisher","first-page":"590683","DOI":"10.3389\/fmicb.2020.590683","volume":"11","author":"S Rezasoltani","year":"2020","unstructured":"Rezasoltani S, Yadegar A, Hatami B, Asadzadeh Aghdaei H, Zali MR. Antimicrobial resistance as a hidden menace lurking behind the COVID-19 outbreak: the global impacts of too much hygiene on AMR. Front Microbiol. 2020;11:590683. Published 2020 Dec 15. https:\/\/doi.org\/10.3389\/fmicb.2020.590683.","journal-title":"Front Microbiol"},{"issue":"7","key":"344_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1179\/2047773215Y.0000000030","volume":"109","author":"F Prestinaci","year":"2015","unstructured":"Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309\u201318. https:\/\/doi.org\/10.1179\/2047773215Y.0000000030.","journal-title":"Pathog Glob Health"},{"key":"344_CR5","unstructured":"WHO. Antimicrobial resistance. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance. Accessed date: 6 June 2021"},{"issue":"Suppl 2","key":"344_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.11604\/pamj.supp.2020.35.23713","volume":"35","author":"CJ Iwu","year":"2020","unstructured":"Iwu CJ, Jordan P, Jaja IF, Iwu CD, Wiysonge CS. Treatment of COVID-19: implications for antimicrobial resistance in Africa. Pan Afr Med J. 2020;35(Suppl 2):119. Published 2020 Jul 20. https:\/\/doi.org\/10.11604\/pamj.supp.2020.35.23713.","journal-title":"Pan Afr Med J"},{"key":"344_CR7","unstructured":"WHO. Clinical guidance for COVID-19. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2021-1 Accessed date: 6 June 2021"},{"key":"344_CR8","doi-asserted-by":"publisher","first-page":"1321487","DOI":"10.1155\/2016\/1321487","volume":"2016","author":"MC Sonmezer","year":"2016","unstructured":"Sonmezer MC, Ertem G, Erdinc FS, Kaya Kilic E, Tulek N, Adiloglu A, et al. Evaluation of risk factors for antibiotic resistance in patients with nosocomial infections caused by Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol. 2016;2016:1321487\u20139. https:\/\/doi.org\/10.1155\/2016\/1321487.","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"1","key":"344_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1039\/C7MD00528H","volume":"9","author":"RJ Melander","year":"2018","unstructured":"Melander RJ, Zurawski DV, Melander C. Narrow-spectrum antibacterial agents. Medchemcomm. 2018;9(1):12\u201321. https:\/\/doi.org\/10.1039\/C7MD00528H.","journal-title":"Medchemcomm."},{"issue":"11","key":"344_CR10","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1093\/jac\/dkaa326","volume":"75","author":"B Beovi\u0107","year":"2020","unstructured":"Beovi\u0107 B, Dou\u0161ak M, Ferreira-Coimbra J, Nadrah K, Rubulotta F, Belliato M, et al. Antibiotic use in patients with COVID-19: a \u2018snapshot\u2019 infectious diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;75(11):3386\u201390. https:\/\/doi.org\/10.1093\/jac\/dkaa326.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"344_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1186\/s12879-020-05374-z","volume":"20","author":"E Sharifipour","year":"2020","unstructured":"Sharifipour E, Shams S, Esmkhani M, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect Dis. 2020;20(1):646. Published 2020 Sep 1. https:\/\/doi.org\/10.1186\/s12879-020-05374-z.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"344_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13613-020-00736-x","volume":"10","author":"D Contou","year":"2020","unstructured":"Contou D, Claudinon A, Pajot O, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care. 2020;10(1):119. Published 2020 Sep 7. https:\/\/doi.org\/10.1186\/s13613-020-00736-x.","journal-title":"Ann Intensive Care"},{"issue":"5","key":"344_CR13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jiph.2021.02.001","volume":"14","author":"M Chedid","year":"2021","unstructured":"Chedid M, Waked R, Haddad E, Chetata N, Saliba G, Choucair J. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health. 2021;14(5):570\u20136. https:\/\/doi.org\/10.1016\/j.jiph.2021.02.001.","journal-title":"J Infect Public Health"},{"key":"344_CR14","unstructured":"Moolla MS, Reddy K, Fwemba I, Nyasulu PS, Taljaard JJ, Parker A, et al. Bacterial infection, antibiotic use and COVID-19: lessons from the intensive care unit. SAMJ. 2021;111(4)."},{"issue":"2","key":"344_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jinf.2020.05.046","volume":"81","author":"L Lansbury","year":"2020","unstructured":"Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Inf Secur. 2020;81(2):266\u201375. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.046.","journal-title":"J Inf Secur"},{"issue":"4","key":"344_CR16","doi-asserted-by":"publisher","first-page":"e0249668","DOI":"10.1371\/journal.pone.0249668","volume":"16","author":"S He","year":"2021","unstructured":"He S, Liu W, Jiang M, et al. Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: a multi-center study. PLoS One. 2021;16(4):e0249668. Published 2021 Apr 5. https:\/\/doi.org\/10.1371\/journal.pone.0249668.","journal-title":"PLoS One"},{"issue":"7","key":"344_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2471\/BLT.20.268573","volume":"98","author":"H Getahun","year":"2020","unstructured":"Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ. 2020;98(7):442\u2013442A. https:\/\/doi.org\/10.2471\/BLT.20.268573 PMID: 32742026; PMCID: PMC7375214.","journal-title":"Bull World Health Organ"},{"issue":"12","key":"344_CR18","doi-asserted-by":"publisher","first-page":"e1453","DOI":"10.1016\/S2214-109X(20)30444-7","volume":"8","author":"AS Ginsburg","year":"2020","unstructured":"Ginsburg AS, Klugman KP. COVID-19 pneumonia and the appropriate use of antibiotics. Lancet Glob Health. 2020;8(12):e1453\u20134. https:\/\/doi.org\/10.1016\/S2214-109X(20)30444-7.","journal-title":"Lancet Glob Health"},{"issue":"10","key":"344_CR19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40261-020-00961-z","volume":"40","author":"CS Kow","year":"2020","unstructured":"Kow CS, Hasan SS. Use of azithromycin in COVID-19: a cautionary tale. Clin Drug Investig. 2020;40(10):989\u201390. https:\/\/doi.org\/10.1007\/s40261-020-00961-z.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"344_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000806","volume":"8","author":"I Gyselinck","year":"2021","unstructured":"Gyselinck I, Janssens W, Verhamme P, Vos R. Rationale for azithromycin in COVID-19: an overview of existing evidence. BMJ Open Respir Res. 2021;8(1):e000806. https:\/\/doi.org\/10.1136\/bmjresp-2020-000806.","journal-title":"BMJ Open Respir Res"},{"issue":"10279","key":"344_CR21","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0140-6736(21)00461-X","volume":"397","author":"PRINCIPLE Trial Collaborative Group","year":"2021","unstructured":"PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397(10279):1063\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(21)00461-X.","journal-title":"Lancet."},{"issue":"2","key":"344_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14787210.2020.1813024","volume":"19","author":"D Echeverr\u00eda-Esnal","year":"2021","unstructured":"Echeverr\u00eda-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, de-Antonio Cusc\u00f3 M, Ferr\u00e1ndez O, Horcajada JP, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti-Infect Ther. 2021;19(2):147\u201363. https:\/\/doi.org\/10.1080\/14787210.2020.1813024.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"2","key":"344_CR23","doi-asserted-by":"publisher","first-page":"bjgpopen20X1010","DOI":"10.3399\/bjgpopen20X101094","volume":"4","author":"K Gbinigie","year":"2020","unstructured":"Gbinigie K, Frie K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP Open. 2020;4(2):bjgpopen20X101094. Published 2020 Jun 23. https:\/\/doi.org\/10.3399\/bjgpopen20X101094.","journal-title":"BJGP Open"},{"key":"344_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jgar.2020.03.009","volume":"22","author":"MR Akpan","year":"2020","unstructured":"Akpan MR, Isemin NU, Udoh AE, Ashiru-Oredope D. Implementation of antimicrobial stewardship programmes in African countries: a systematic literature review. J Glob Antimicrob Resist. 2020;22:317\u201324. https:\/\/doi.org\/10.1016\/j.jgar.2020.03.009.","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"344_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.4269\/ajtmh.20-1485","volume":"104","author":"YA Adebisi","year":"2020","unstructured":"Adebisi YA, Ekpenyong A, Ntacyabukura B, Lowe M, Jimoh ND, Abdulkareem TO, et al. COVID-19 highlights the need for inclusive responses to public health emergencies in Africa [published online ahead of print, 2020 Dec 15]. Am J Trop Med Hyg. 2020;104(2):449\u201352. https:\/\/doi.org\/10.4269\/ajtmh.20-1485.","journal-title":"Am J Trop Med Hyg"},{"key":"344_CR26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.11604\/pamj.2021.38.230.27325","volume":"38","author":"YA Adebisi","year":"2021","unstructured":"Adebisi YA, Alaran AJ, Bolarinwa OA, Akande-Sholabi W, Lucero-Prisno DE. When it is available, will we take it? Social media users\u2019 perception of hypothetical COVID-19 vaccine in Nigeria. Pan Afr Med J. 2021;38:230. Published 2021 Mar 2. https:\/\/doi.org\/10.11604\/pamj.2021.38.230.27325.","journal-title":"Pan Afr Med J"}],"container-title":["Tropical Medicine and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-021-00344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41182-021-00344-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-021-00344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:23:55Z","timestamp":1624436635000},"score":1,"resource":{"primary":{"URL":"https:\/\/tropmedhealth.biomedcentral.com\/articles\/10.1186\/s41182-021-00344-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1186\/s41182-021-00344-w","relation":{},"ISSN":["1349-4147"],"issn-type":[{"value":"1349-4147","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"19 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}